The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s ...

Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data ...

When my daughter was diagnosed with breast cancer, writing our truth helped me and others face the harsh realities and ...

Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, ...

Kim White's battle with adrenocortical carcinoma highlights her resilience and determination to live life fully despite her ...

July brought major breast cancer updates, and CURE is sharing the latest, as recent developments underscore how quickly the landscape continues to evolve.

Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but ...

Dr. Jacob Sands discusses progress in lung cancer treatment, as well as what patients should understand about how their care options may evolve over time.

Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer ...

Imfinzi plus chemo cut progression or death risk in early gastric cancer; the FDA's decision is expected late 2025 following breakthrough designation.